gsk whirlwind owes khryanin 28 million. and according to a court decision, gsk must return this money. this is a copy of another loan agreement for 9 million 600,000 rubles. will have to return 36 million on the face of obvious vested interests. uh, the current chairman. loshkareva aleksey anatolyevich, a citizen of khryanin, a filed a bankruptcy petition for the bankruptcy of the entire gsk . that is, now there is actually a discussion about such an raider seizure of the lawyers of the garage cooperative. he has been leading for 10 years. here the business of the company declares that he is openly threatened by the chairman said, i told you very convincingly, i beg you, do not get involved in this matter. i can handle it myself if i look, uh, by proxy, these documents for another day. at me power of attorney will no longer experts are sure lyshkarev their reanin could. conspire the chairman the chairman of which by recognizing the claim he caused damage to the gsk if the gsk has some property they would like to clean up. t

what are the difference between gsk and roche and others?rmance of astrazeneca, which you do not mention, versus pfizer. sweet a few years ago, pfizer was trying to buy -- quite a few years ago, pfizer was trying to buy astrazeneca. that just tells you that, yes, you are right. individual stocks do matter. as a whole, pharma is a different sector. perhaps there is an environment where there are risks that people are worried about and that is where it plays well, but within it, you have very different stories. we had a perfect example today. i do not know where it is now. maybe it hit 40%. alix: how much of this is rereading post-covid? astrazeneca versus moderna versus pfizer. pfizer and missy are not were the darlings of the covid vaccine. now that that is working its way out, how we look at outperformer's cap sam: you have to back that up. pfizer will not have another $100 billion year for a while. i hope we do not have a so outbreak or something that would take us there. but you have to look at the underlying. there is excitement in the d

growth came in stronger than expected at 5% gsk beat expectations with its first quarter earnings withue jumping to 7 million pounds it's seen an increase in its shingles vaccine the company reaffirmed its full year designs emily, also a pleasure great to have you in person this time around. let me kick off by asking what stood out to you so far from european earnings season looking across the big names, we've got pretty much every one of those beating expectations. what's your takeaway >> thanks for having me. i would say everyone seems to be so far, so good. we saw a strong beat and high guidance rated and roche, you know, they are seeing the larm co large covid decline. gsk, a beat versus expectations, maintained guidance for the year the sector's done quite well, but it seems like everything is still going well. >> i know one stock -- we'll get to it in a second. joumanna, if you want to jump in and talk any other earnings? >> i just wanted to ask you about margins and sort of your outlook there because there were signs because of the may crow economic environmental markets would h

unilever and gsk and rosche. translating to the broader section in the ftse 100 down 6 points. the focus in earnings has been the banks. let's take you to the key results from deutsche bank the stock is up 2% posting a first quarter net profit of 3.1 billion euro it was boosted by profits from higher interest rates. we spoke to the cfo earlier who was feeling confident about the results. switching to uk, barclays beat on the first quarter profit and strong consumer banking unit it posted 2.6 billion pounds in pre-tax profit and net income rising 47% the stock is performing well up 5% finally, samsung is another stock we are looking at which is up .80% despite the record $3.4 billion loss frank. >> joumanna bercetche in the london newsroom. thank you very much. >>> time for the check of the top corporate stories, including a d.c. showdown taking shape silvana henao is back with those headlines. >> frank, kevin mccarthy's plan to raise the debt ceiling clearing that chamber. house members voting to approve the bill

committees that are pausing or not renewing membership to include asda, natwest, octopus, lloyd script, gskhip. this will cause all kinds of problems for the business lobbying group and i'm sure we will be hearing more about that here on bbc news on monday morning. to germany now. to germany now where representatives from 50 countries have been meeting to discuss how they can give ukraine more support in the war effort. the us defence secretary, lloyd austin, has said more tanks will arrive in germany in the next few weeks to help train ukrainian forces. speaking at the end the talks, mr austin said he was confident the mi abrams tanks would help troops continue to make gains on the battlefield. he also detailed some of the support provided over the last past year. you know, putin made a series of grave miscalculations. when he ordered the invasion of ukraine more than a year ago, he thought that ukraine wouldn't dare to fight back. but ukraine is standing strong with the help of its partners. putin thought that our unity would fracture. but russia's cruel war of choice has only brought us

. >> gsk >> for those who are looking for deals, i am hearing green shoots, some positive, because ike, yeah, you know what, things are feeling a little better we'll see if we get -- not in this area, per se. i'm just saying, generally >> for public or private >> for public companies. >> well, there are so many biotech, but the -- and i'm involved with a drug myself, and you get phase two, and if it's any good and it's something new, phase three is just millions of dollars. so, it's like, if you're prometheus, they had the money to do it, but, you know, merck needed them more than prometheus needed them. i saw the same thing with biohaven, with their migraine drug pfizer just paid a fortune for it vlad, who runs biohaven, knew he couldn't get anyone to know about the drug it's called neurtech i'm shocked there's this migraine medicine that pfizer has, and no one's heard of it. i brought them on to talk about it because no one's heard of this stupid -- not stupid. it's a great drug. it gets rid of your migraine in 15 minutes, and i see people say, it's horrible take this. but they cou

john lewis, gsk and british among and british land are among dozens of companies which have decided pausees like amazon and small and medium sized enterprises. so andy mayer mayer is the chief operating officer at the institute of economic affairs and sir vince cable is, of course, the former leader of the liberal democrats. and he served in cabinet as business secretary. and andy . business secretary. and andy. welcome to gb news. you must have had a lot of contact with the cbi. did anything in your experience with the cbi prepare you for the series of scandals in which it's now embroiled ? in which it's now embroiled? well, it's very regrettable. i mean, i've been dealing with the cbi on and off and previously from being a public affairs head in major corporations for about 15 to 20 years and most of the work of the cbi is not this high profile headline stuff we're seeing at the moment, but it's very low level detailed regulatory affairs work. but they're looking at the- g but they're looking at the entire twstness— they're looking at the entire business operating environment and busine